Michael Graner received his PhD in Biochemistry from the University of Illinois followed by post-doctoral and research faculty work at the University of Arizona, shifting gears from the Drosophila extracellular matrix to cancer immunotherapy. He then took at faculty position at Duke University’s Tisch Brain Tumor Center, followed by his current position as Professor in Neurosurgery at the University of Colorado Denver (Anschutz Medical Campus). He is also a member of the University of Colorado Cancer Center, the Colorado Clinical and Translational Sciences Institute, the MAVRC Program, and holds a Visiting Professorship Appointment at the Shenzhen Third People’s Hospital (China) and an adjunct faculty appointment at Colorado State University. Graner has a long-standing interest in cell stress responses, which led to cancer vaccine development (including one in clinical trials), which somehow led to the world of extracellular vesicles (EVs). His lab currently concentrates on signaling mechanisms involving EVs, in particular the transfer of stressed phenotypes from stressed tumor cells to unstressed ones via EVs.

Dr. Sven Kreutel studied biology at the University of Hohenheim in Stuttgart, Germany. After his graduation in biology, he received his PhD in microbiology and protein biochemistry at the University of Hohenheim under Prof. Dr. Andreas Kuhn and Dr. Dorothee Kiefer working on the light sensing and signal transduction in photosynthetic bacteria. Since then he worked in different sales and sales manager positions within the life science industry from clinical research over biology to nanoparticle sciences. In 2021 he was appointed as CEO of the American subsidiary of Particle Metrix.